Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2679-2687

  Sharma, Amit ^a   Yee, Jerry ^b   Gandra, Shravanthi R ^c   Khan, Irfan ^c   Petersen, Jeffrey ^c  

^a Boise Kidney and Hypertension Institute   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c AMGEN INC   (United States)

Author keywords

Anemia; Darbepoetin alfa; Dialysis; Dose conversion; End stage renal disease; Epoetin alfa

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; DOSE CALCULATION; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ECONOMICS, PHARMACEUTICAL; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMODIALYSIS UNITS, HOSPITAL; HUMANS; KIDNEY DISEASES; MALE; MEDICAL AUDIT; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77958129117     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.526598     Document Type: Article

References (41)

1. USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: United States Renal Data Systems, 2009
2. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-48
3. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803-12
4. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Amer Coll Cardiol 2001;38:955-62
5. Astor BC, Coresh J, Heiss G, et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006;151:492-500 (Pubitemid 43144756)
6. Ma JZ, Ebben J, Xia H, et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-19
7. McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-36
8. Xia H, Ebben J, Ma JZ, et al. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999;10:1309-16
9. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ (Clinical research edn) 1990;300:573-8
10. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
11. Padhi D, Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006;45:503-10
12. Mahajan S, Boulton H, Gokal R. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. J Nephrol 2004;17:687-92
13. Vanrenterghem Y, Barany P, Mann JF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62:2167-75
14. Fang YW, Chang CH. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients. Perit Dial Int 2009;29:199-203
15. Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18:362-9
16. Brunkhorst R, Bommer J, Braun J, et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004;19:1224-30
17. Locatelli F, Villa G, Backs W, et al. A phase 3, multicentre, randomized, double-blind, non-inferiority trial to evaluate the efficacy of Aranesp (darbe-poetin alfa) once every 2 weeks (Q2W) vs Aranesp once weekly (QW) in patients on haemodialysis (HD). [abstract]. Nephrol Dial Transplant 2005; 20(Suppl. 5):v260
18. Nissenson AR. Dosing darbepoetin alfa. Am J Kidney Dis 2002;40:872
19. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
20. Scott SD. Dose conversion from recombinant human erythropoietin to darbe-poetin alfa: recommendations from clinical studies. Pharmacotherapy 2002;22(9 PT 2):160S-5S
21. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110-18
22. Graf H, Lacombe J-L, Braun J, et al. Novel erythropoiesis stimulating protein (NESP) effectively maintains Hemoglobin (Hb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients [abstract]. J Am Soc Nephrol 2000;11:A1317
23. Vanrenterghem Y, Barany P, Mann J. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week [abstract]. J Am Soc Nephrol 1999; 10:A1365
24. Barron JJ, Grochulski WD, Mody SH, et al. Erythropoietic therapy: dosing patterns and calculated cost assessment for pre-dialysis chronic kidney disease patients in managed care setting. Pharm Ther 2007;32:661-70
25. Bock HA, Hirt-Minkowski P, Brunisholz M, et al. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant 2008;23:301-8
26. Cremieux PY, Van Audenrode M, Lefebvre P. The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. Curr Med Res Opin 2006;22:2329-36
27. Duh MS, Mody SH, McKenzie RS, et al. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. Drugs Aging 2006;23:969-76
28. Duh MS, Mody SH, Scott McKenzie R, et al. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clin Ther 2006;28:1443-50
29. Hirai T, Sugiya N, Nakashima A, et al. Switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients: dose conversion ratio. Nephron 2009;111:c81-6
30. Hymes J, Bickimer T, Jackson JH, et al. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. Curr Med Res Opin 2007;23:1931-7
31. Laliberte F, Lefebvre P, Vekeman F, et al. Drug utilization and cost considerations of predialysis chronic kidney disease patients receiving erythropoiesis-stimulating agents through pharmacy benefits [abstract]. Am J Kidney Dis 2008;51:a25, no 130
32. Papatheofanis F, Smith C, Mody S, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. Am J Ther 2007; 14:322-7
33. Papatheofanis FJ, McKenzie RS, ModySH, etal. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin 2006;22:837-42
34. Raymond CB, Wazny LD, Vercaigne LM, et al. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios. CANNT J 2008;18:39-43
35. Vekeman F, McKenzie RS, Lefebvre P, et al. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Am J Health Syst Pharm 2007;64:1943-9
36. CMS. End-Stage Renal Disease (ESRD) Payment Regulations and Notices. Available at: http://wwwcmshhsgov/ESRDPayment/PAY/itemdetailasp? filterType=none&filterByDID=-99&sortByDID=4&sortOrder= descending& itemID=CMS1228517&intNumPerPage=10 [Last accessed 13 October 2009]
37. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-43
38. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992;51:76-89
39. CMS. Rules and regulations. Fed Regist 2004;69:65796-7
40. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37(1 Suppl. 1):S182-238
41. Horowitz J, Agarwal A, Huang F, et al. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm 2009;15:741-50